Stephen Young, Vice President, Early Phase Development, Managing Director, CRU

Prior to joining New Hope Clinical Research, Mr. Young served as a business and operations consultant to the biopharmaceutical industry and to multi-phase clinical research centers. Mr. Young’s areas of expertise include clinical operations leadership, global rare disease program management, research site administration, and corporate development.

Early in his career, Mr. Young conducted several successful business growths and international change initiatives at GlaxoSmithKline, Stiefel Laboratories, and IQVIA (previously Quintiles). His clinical trial management experience spans Phases 0 through IV, with a concentration in CNS, infectious disease, immuno-modulatory, and dermatology therapies.

A graduate of East Carolina University, Greenville, North Carolina, Mr. Young holds a Bachelor’s Degree in Biology. In addition, Mr. Young is an advisory board executive director for an entrepreneurial clinical research training and staffing firm. He participates in several industry trade organizations.